{"url":"https://newsforagent.com/news/2026-11-10/aro-biotherapeutics-abx1200-myositis-acr","markdown_url":"https://newsforagent.com/news/2026-11-10/aro-biotherapeutics-abx1200-myositis-acr.md","title":"Aro Biotherapeutics Previews 2027 Myositis Trial for ABX1200","headline":"Aro Biotherapeutics Presents ABX1200 Myositis Data at ACR 2026, Plans Clinical Studies in 2027","description":"Aro Biotherapeutics presented preclinical ABX1200 data at ACR Convergence 2026 showing reduced CD40 expression in myositis models.","section":"Research & Clinical Trials","published_at":"2026-11-10T21:54:28+00:00","modified_at":"2026-11-10T21:54:28+00:00","author":"News Desk","key_takeaways":["Aro Biotherapeutics presented preclinical ABX1200 data in an oral session at ACR Convergence 2026 in Orlando, Florida.","ABX1200 reduced CD40 mRNA in macrophages and myotubes in vitro and lowered CD40 and chemokine upregulation in a preclinical muscle inflammation model.","CEO Purnanand Sarma said Aro Biotherapeutics plans to begin clinical studies of ABX1200 in 2027."],"companies":[{"name":"Aro Biotherapeutics","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00008wg/aro-biotherapeutics","website":"https://www.arobiotx.com"},{"name":"Karolinska Institutet","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0003kt4/karolinska-institutet","website":"http://www.ki.se"}],"source":{"publisher":"GlobeNewswire","title":"Aro Biotherapeutics Reports Therapeutic Potential of Centyrin–CD40 siRNA Conjugate for the Treatment of Inflammatory Myositis","url":"https://www.globenewswire.com/news-release/2026/11/10/3400260/0/en/aro-biotherapeutics-reports-therapeutic-potential-of-centyrin-cd40-sirna-conjugate-for-the-treatment-of-inflammatory-myositis.html"},"other_sources":[{"publisher":"Business & Financial","url":"https://menafn.com/1111892416/Biotech-Stock-Silexion-Therapeutics-Corp-NASDAQ-SLXN-Soars-On-Update-And-First-Quarter-Results"},{"publisher":"Naver","url":"https://n.news.naver.com/mnews/article/018/0006398425"},{"publisher":"PRLog","url":"https://www.prlog.org/13179485-ting-therapeutics-advances-tt004-into-phase-ib-trial-to-reduce-cisplatin-toxicity.html"},{"publisher":"Business & Financial","url":"https://menafn.com/1111873025/Age-Related-Macular-Degeneration-Pipeline-2026-Therapeutic-Candidates-Clinical-Trial-Insights-And-Companies-Leading-Drug-Development-Astellas-Pharma-Iveric-Bio-Apellis-Pharma-Novartis-Alkeus"}],"tags":["Research & Clinical Trials","Aro Biotherapeutics","Karolinska Institutet"],"body_markdown":"Aro Biotherapeutics presented preclinical data on November 10, 2026 showing that ABX1200, its CD71-Centyrin CD40-siRNA conjugate, reduced CD40 expression in models of inflammatory myositis, and said it plans to begin clinical studies in 2027. The findings were given in an oral presentation at ACR Convergence 2026 in Orlando, Florida, according to [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/10/3400260/0/en/aro-biotherapeutics-reports-therapeutic-potential-of-centyrin-cd40-sirna-conjugate-for-the-treatment-of-inflammatory-myositis.html).\n\n## Aro Biotherapeutics' ABX1200 Myositis Findings\n\n[Aro Biotherapeutics](https://akta.pro/company-profiles/00008wg/aro-biotherapeutics) is a clinical-stage Philadelphia biotechnology company developing tissue-targeted siRNA medicines on its Centyrin protein platform. The myositis work was done with the [Karolinska](https://akta.pro/company-profiles/0003kt4/karolinska-institutet) Institute, whose Professor of Rheumatology Dr. Ingrid Lundberg said: \"Because myositis is a muscle disease, patients stand to benefit from the development of muscle-targeted therapies like ABX1200, and this collaboration has taken steps to advance this approach.\"\n\nPatient muscle samples were analyzed by RNA sequencing and immunohistochemistry. RNA sequencing showed elevated CD40 expression in muscle from inclusion body myositis patients and predominant CD40L expression in CD4+ central memory T cells in blood and in T cells infiltrating myositis muscle. Immunohistochemistry showed CD40 co-expression with muscle-infiltrating macrophages, and CD40 expression correlated with high serum creatine kinase levels and disease activity scores.\n\nABX1200 reduced CD40 mRNA in vitro in macrophages and myotubes. In a preclinical model of muscle inflammation, it reduced the upregulation of CD40 and of chemokines that are upregulated in idiopathic inflammatory myopathies. CEO Purnanand Sarma said: \"We are planning to begin clinical studies in 2027.\" ABX1200 is investigational and has not been evaluated for safety or efficacy by any regulatory authority.\n\n## Aro Biotherapeutics' Funding and Pipeline Record\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Aro Biotherapeutics has raised total funding of $166.5 million across four rounds, most recently a $41.5 million Series B in November 2023 led by Cowen Healthcare Investments. The same records list a $88 million Series A closed in January 2021 and a $13 million start-up investment raised in December 2018.\n\nThe records also show positive Phase 1b topline results reported in March 2026 for ABX1100 in late-onset Pompe disease, with approximately 62% sustained GYS1 mRNA knockdown in muscle and a mean FVC improvement of approximately 2.5% at 5 months, with no serious adverse events.\n\n## siRNA Peers Advance Their Own Programs\n\n[Silexion Therapeutics](https://menafn.com/1111892416/Biotech-Stock-Silexion-Therapeutics-Corp-NASDAQ-SLXN-Soars-On-Update-And-First-Quarter-Results) received Israeli Ministry of Health approval to start a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, [Business & Financial](https://menafn.com/1111873025/Age-Related-Macular-Degeneration-Pipeline-2026-Therapeutic-Candidates-Clinical-Trial-Insights-And-Companies-Leading-Drug-Development-Astellas-Pharma-Iveric-Bio-Apellis-Pharma-Novartis-Alkeus) reported on October 30, 2026. [OliX Pharmaceuticals](https://n.news.naver.com/mnews/article/018/0006398425) resubmitted a New Zealand trial application for OLX301A after it was rejected over administrative issues, Naver reported on October 28, 2026. [Ting Therapeutics](https://www.prlog.org/13179485-ting-therapeutics-advances-tt004-into-phase-ib-trial-to-reduce-cisplatin-toxicity.html) received China IND approval for TT004 and began a Phase Ib trial in head and neck cancer, PRLog reported on October 28, 2026.\n\n## Aro Biotherapeutics' 2027 Clinical Plan\n\nAro Biotherapeutics said it plans to begin clinical studies of ABX1200 in 2027. The company's announcement is posted on its [website](https://www.arobiotx.com).\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}